Montezano Augusto C, Kuriakose Jithin, Hood Katie Y, Sin Yuan Yan, Camargo Livia L, Namkung Yoon, Castro Carlos H, Santos Robson A, Alves-Lopes Rheure, Tejeda Gonzalo, Passaglia Patricia, Basheer Sehrish, Gallen Emily, Findlay Jane E, Awan Fazli R, Laporte Stéphane A, MacLean Margaret R, Baillie George S, Touyz Rhian M
Research Institute of McGill University Health Centre, Montreal, Quebec, Canada (A.C.M., L.L.C., Y.N., S.A.L., R.M.T.).
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.K., K.Y.H., Y.Y.S., G.T., E.G., J.E.F., G.S.B.).
Hypertension. 2025 Feb;82(2):267-281. doi: 10.1161/HYPERTENSIONAHA.124.22693. Epub 2024 Dec 5.
Ang-(1-7) (angiotensin (1-7)) via MasR (Mas receptor) opposes vaso-injurious actions of Ang II (angiotensin II) as shown in models of pulmonary hypertension. The underlying mechanisms remain unclear. We hypothesized cross talk between Ang-(1-7) and the protective arm of the ET-1 (endothelin-1) system involving MasR and ETR (endothelin receptor type B).
To address this, we studied multiple models: in vivo, in a mouse model of ET-1-associated vascular injury (hypoxia-induced pulmonary hypertension); ex vivo, in isolated mouse arteries; and in vitro, in human endothelial cells.
Pulmonary hypertension mice exhibited pulmonary vascular remodeling, endothelial dysfunction, and ET-1-induced hypercontractility. Ang-(1-7) treatment (14 days) ameliorated these effects and increased the expression of vascular ETR. In human endothelial cells, Ang-(1-7)-induced activation of eNOS (endothelial NO synthase)/NO was attenuated by A779 (MasR antagonist) and BQ788 (ETR antagonist). A779 inhibited ET-1-induced signaling. Coimmunoprecipitation and peptide array experiments demonstrated the interaction between MasR and ETR. Binding sites for ETR were mapped to MasR (amino acids 290-314). Binding sites for MasR on ETR were identified (amino acids 176-200). Peptides that disrupt MasR:ETR prevented Ang-(1-7) and ET-1 signaling. Using high-throughput screening, we identified compounds that enhance MasR:ETR interaction, which we termed enhancers. Enhancers increased Ang-(1-7)-induced eNOS activity, NO production, and Ang-(1-7)-mediated vasorelaxation, and reduced contractile responses.
We identify cross talk between Ang-(1-7) and ET-1 through MasR:ETR interaction as a novel network that is vasoprotective. Promoting coactivity between these systems amplifies Ang-(1-7) signaling, increases ET-1/ETR-mediated vascular actions, and attenuates the injurious effects of ET-1. Enhancing Ang-(1-7)/MasR:ET-1/ETR signaling may have therapeutic potential in conditions associated with vascular damage.
在肺动脉高压模型中,血管紧张素(1-7)[Ang-(1-7)] 通过Mas受体(MasR)对抗血管紧张素II(Ang II)的血管损伤作用。其潜在机制仍不清楚。我们推测Ang-(1-7) 与内皮素-1(ET-1)系统的保护分支之间存在涉及MasR和B型内皮素受体(ETR)的相互作用。
为解决这一问题,我们研究了多种模型:体内,采用ET-1相关血管损伤的小鼠模型(低氧诱导的肺动脉高压);体外,采用分离的小鼠动脉;以及体外,采用人内皮细胞。
肺动脉高压小鼠表现出肺血管重塑、内皮功能障碍和ET-1诱导的高收缩性。Ang-(1-7) 治疗(14天)改善了这些效应,并增加了血管ETR的表达。在人内皮细胞中,A779(MasR拮抗剂)和BQ788(ETR拮抗剂)减弱了Ang-(1-7) 诱导的内皮型一氧化氮合酶(eNOS)/一氧化氮(NO)激活。A779抑制ET-1诱导的信号传导。免疫共沉淀和肽阵列实验证明了MasR与ETR之间的相互作用。ETR的结合位点定位于MasR(氨基酸290 - 314)。ETR上MasR的结合位点也被确定(氨基酸176 - 200)。破坏MasR:ETR的肽可阻止Ang-(1-7) 和ET-1信号传导。通过高通量筛选,我们鉴定出增强MasR:ETR相互作用的化合物,我们将其称为增强剂。增强剂增加了Ang-(1-7) 诱导的eNOS活性、NO生成以及Ang-(1-7) 介导的血管舒张,并降低了收缩反应。
我们确定了Ang-(1-7) 与ET-1之间通过MasR:ETR相互作用的相互作用,这是一个新的血管保护网络。促进这些系统之间协同作用可放大Ang-(1-7) 信号传导,增加ET-1/ETR介导的血管作用,并减弱ET-1的损伤作用。增强Ang-(1-7)/MasR:ET-1/ETR信号传导在与血管损伤相关的病症中可能具有治疗潜力。